Vertex Pharmaceuticals Inc (VRTX)
Vertex Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing medicines for serious diseases in the United States, Europe, and other international markets. Its commercial portfolio is centered on cystic fibrosis, with marketed products including TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO. The company is also advancing programs in sickle cell disease and transfusion dependent beta thalassemia through CASGEVY, and it markets JOURNAVX for acute pain in adults. Vertex’s development pipeline includes VX-522, inaxaplin, VX-264, VX-670, and VX-407 across additional genetic and kidney-related disorders. The company sells its products mainly through specialty pharmacies and distributors, as well as wholesalers, retail pharmacies, hospitals, and clinics. Founded in 1989, Vertex is headquartered in Boston, Massachusetts, and its common stock trades on NASDAQ under the symbol VRTX.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-VRTX
|
$479.28
|
-0.4% Downside
|
Fair
|
$554.91
|
15.4% Upside
|
Fair
|
Great
|
—
|
—
|
—
|
0.0%
|
August 3, 2026
|
28.2x
|
6.3x
|
10.0x
|
122 B
|
111.1 B
|
1.6%
|
99.7%
|
12.6
|
—
|
85.5%
|
